Compare Sanofi SA (SNY) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Sanofi SA trades at $42.96 (market cap $103.41B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.79. The key difference: Sanofi SA pays a 5.65% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | XLY | |
|---|---|---|
Market Cap | $103.41B | — |
Sector | Health | — |
52-Week High | $52.34 | $124.52 |
52-Week Low | $41.33 | $105.64 |
Enterprise Value | $123.44B | — |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
XLY trades at $113.99, down 0.8% today amid bearish technical signals with 18 sell indicators versus 3 buy signals. The ETF maintains 100% analyst buy consensus despite missing key valuation metrics. Recent news highlights consumer discretionary sector opportunities, with XLY positioned as a potential sleeper ETF for Q3 2026 given resilient consumer spending trends and economic conditions.
The outlook remains cautiously optimistic with strong analyst support, though technical weakness and sector concentration risks warrant monitoring. Upside potential exists from consumer spending resilience and economic broadening, while downside risks include market volatility and inflationary pressures affecting discretionary purchases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
